A stochastic thermodynamics framework for investigating neural responses to fo-cused ultrasound.

(A) Experimental setup from Murphy et al. [36]. A scalp transducer (550 kHz) delivered tFUS to the central medial thalamus (CMT) of freely moving GCaMP-expressing mice while neural activity was recorded via fiber photometry. Stimulation was applied on-target (di-rectly above the CMT) and off-target (3 mm lateral offset). (B) Fluorescence traces. Each trial consisted of a 5 s baseline, 5 s sonication, and recovery period (first 10 s analysed). Gray traces show individual trials; the dark green trace shows the trial average. (C) Stochastic thermodynam-ics framework. tFUS is modeled as an external work input to a neural system that is already far from thermodynamic equilibrium and weakly coupled to an effective bath. The resulting stochastic dynamics reflect bath-driven fluctuations, internal entropy production, and heat dissipation back to the environment. (D) Ordinal EPR estimation pipeline. The calcium signal is delay-embedded, and each embedding vector is mapped to its ordinal pattern. The symmetrised Kullback–Leibler divergence between the forward and backward ordinal distributions yields Dsym, an estimator of the EPR.

Distinct dose-response of temporal irreversibility and calcium amplitude.

We mea-sured the change in both EPR and GCaMP during and immediately after 2.5 Hz sonication of the central medial thalamus (CMT). Stimulation was delivered on-target and with a 3 mm off-set (off-target) between tFUS and GCaMP acquisition. (A,B) EPR (Dsym) in the on-target (A) and off-target (B) conditions during baseline (grey), stimulation (red), and recovery (green). The largest deviations from baseline are found at moderate intensities. Interestingly, the non-monotonic dose-response is also apparent (but muted) during off-target stimulation, despite the absence of a corresponding calcium response. (C,D) GCaMP amplitude in the on-target (C) and off-target (D) conditions. Unlike EPR, GCaMP shows a largely monotonic dose-response, with no response during off-target sonication. (E) Baseline-subtracted EPR (ΔDsym), shown for on-target/off-target stimulation and recovery. Contrast between on-and off-target is largest in the recovery period. (F) Baseline-subtracted GCaMP (ΔGCaMP). The contrast between on-and off-target increases with intensity. Boxes show the mean ±1 SEM across animals; points denote individual animals.

Dose-response relationships for calcium amplitude and EPR.

Each readout was mod-elled with a mixed-effects model following Eq. 4. Only the on-target main effect and its dose interactions are shown; these terms capture on-target-specific effects of acoustic intensity on the corresponding outcome measure. ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001.

Dissociation between irreversibility and calcium amplitude immediately after son-ication.

(A) Dual-axis overlay of on-target ΔDsym (blue, left axis) and ΔGCaMP (orange, right axis) during stimulation. (B) Same as (A) but now shown for the recovery period. The change in EPR peaks at moderate intensities while calcium amplitude is largely monotonic with dose. Error bars: ±1 SEM. (C) Scatter of ΔDsym versus ΔGCaMP during stimulation (each marker corresponds to one animal×intensity combination, n = 30). Raw and partial correlations are both positive (r = 0.58, p < 0.001; rpartial = 0.63, p < 0.001). (D) During recovery, the correlation vanishes (r = 0.02, p = 0.927; rpartial = 0.16, p = 0.409), indicating that post-sonication EPR is decoupled from fluorescence amplitude despite both measures being significantly elevated relative to baseline.

EPR cannot be explained by calcium amplitude.

To identify whether changes in EPR can be accounted for by concomitant changes in calcium amplitude, we analyzed the relationship between the change in GCaMP (recovery versus baseline), baseline irreversibility, and the irre-versibility measured during recovery. (A) The change in GCaMP after sonication (ΔGCaMP) rises strongly with dose after on-target tFUS. (B) The EPR after sonication (Dsym) peaks at interme-diate intensity and falls off at higher doses. (C) The residual EPR after regressing out ΔGCaMP and baseline EPR: the residual is positive at low-to-moderate on-target doses and negative at the highest on-target doses. Error bars: ±1 SEM across animals. (D) Residual EPR versus ΔGCaMP, coloured by intensity. We fit a set of mixed models to determine whether the residual EPR has a dose-dependence, and if so, whether the dose-dependence is specific to on-target sonication. Within the on-target condition, dose remained significant after accounting for baseline EPR and ΔGCaMP (χ2(2) = 13.55, p = 0.001). Allowing dose terms to differ between on-target and off-target further improved fit (χ2(3) = 27.23, p < 0.001).

Baseline irreversibility modulates EPR response during but not after stimulation.

Vertical axes show the change in irreversibility for on-target (dark blue) and off-target (light blue) trials pooled across all six acoustic intensities and stratified by baseline EPR tercile. (A) During stimulation, the change in EPR is significantly modulated by baseline irreversibility (baseline-EPR × condition interaction: p = 0.003). Trials with lower prestimulation EPR respond more strongly to tFUS in a target-specific manner. (B) In contrast, the change in EPR measured dur-ing recovery is not significantly modulated by baseline irreversibility (p = 0.592). Error bars: ±1 SEM.

Baseline EPR predicts GCaMP response beyond baseline GCaMP and intensity.

(A,B) Added-variable (partial regression) plots for stimulation (A) and recovery (B), shown for on-target trials only. Each point is a single trial coloured by acoustic intensity; axes show residu-als after removing baseline GCaMP, intensity, and animal random effects from both baseline EPR (x-axis) and GCaMP (y-axis). The negative slope indicates that higher prestimulation irreversibil-ity predicts weaker calcium responses. (C,D) Mean adjusted GCaMP (residualized for baseline GCaMP and intensity) by baseline-EPR tercile during stimulation (C) and recovery (D) for on-target (dark orange) and off-target (light orange) conditions. After removing the effects of baseline amplitude and dose, on-target responses still decrease with baseline EPR (likelihood-ratio test for adding baseline EPR: stimulation χ2(1) = 5.04, p = 0.025; recovery χ2(1) = 4.17, p = 0.041). Error bars: ±1 SEM.

Per-animal ΔDsym dose-response: 2.5 Hz on-target.

Each row shows one animal’s ΔDsym as a function of acoustic intensity; left column: stimulation, right column: recovery. All panels share a common y-axis to facilitate comparison across animals. One animal (cmtb3, gray italic) was excluded from the primary analysis because it did not show any GCaMP response (see Supplementary Figures S6–S7). Among the remaining 5 animals, a non-monotonic recovery profile peaking between 1.2 and 3.7 W/cm2 is visible in 4, indicating that the group-level quadratic effect is not driven by a single subject.

Per-animal ΔDsym dose-response: 2.5 Hz off-target.

Same format as Figure S1. Inter-estingly, off-target stimulation generates an inverted-U dose-response in 3 of 5 animals. During the recovery period, EPR changes fluctuate around zero with no systematic intensity dependence.

EPR and GCaMP dose-response at 20 Hz PRF.

Same layout as Figure 2 but for 20 Hz stimulation of the CMT. Murphy et al. [36] reported an offline inhibition of calcium amplitude at this configuration. We were unable to resolve a main effect of on-target stimulation on the GCaMP amplitude. Similarly, the corresponding analysis of EPR did not resolve a significant main effect of on-target sonication during stimulation (p = 0.940), although a nominally significant EPR reduction was present during recovery (p = 0.044).

Stimulation-window EPR cannot be fully explained by calcium amplitude.

Same analysis as Figure 4 but applied to the stimulation window rather than recovery. (A) The change in GCaMP during sonication (ΔGCaMP) rises strongly with dose after on-target tFUS, while off-target remains near zero. (B) The EPR during sonication (Dsym) shows condition-specific dose structure. (C) The residual EPR after regressing out ΔGCaMP and baseline EPR: on-target residual dose structure is present but weaker than in the recovery analysis (Figure 4C). Error bars: ±1 SEM across animals. (D) Residual EPR versus ΔGCaMP, coloured by intensity. Within the on-target condition, dose remained significant after accounting for baseline EPR and ΔGCaMP (χ2(2) = 7.28, p = 0.026). Allowing dose terms to differ between on-target and off-target fur-ther improved fit (χ2(3) = 15.27, p = 0.002). Unlike recovery, however, the ΔGCaMP covariate remained strongly positive (β = +0.181, p < 0.001), indicating that stimulation-window EPR is only partially dissociated from fluorescence amplitude.

Correlation between ΔDsym and ΔGCaMP across conditions and windows at 2.5 Hz.

Each point represents one animal×intensity combination; colours denote acoustic inten-sity. (A) On-target, stimulation: r = 0.58, p < 0.001. (B) On-target, recovery: r = 0.02, p = 0.927. (C) Off-target, stimulation: r = 0.03, p = 0.868. (D) Off-target, recovery: r = −0.26, p = 0.167. Main text Figure 3C,D shows on-target panels only.

Per-animal ΔGCaMP dose–response: 2.5 Hz on-target.

Each row shows one ani-mal’s baseline-subtracted GCaMP amplitude as a function of acoustic intensity; left column: stim-ulation, right column: recovery. All panels share a common y-axis. One animal (cmtb3, gray italic) was excluded from analysis as it did not exhibit a calcium response during or after stimula-tion. Remaining animals show positive responses that increase with intensity, consistent with the monotonic group-level dose-response (Figure 2).

Per-animal ΔGCaMP dose–response: 2.5 Hz off-target.

Same format as Figure S6. Off-target changes remain near zero with no consistent dose dependence.

Hierarchical mixed-model tests: EPR dose structure beyond baseline and calcium amplitude.

Each row reports a likelihood-ratio (LR) test between nested models. Model A (base-line + amplitude only): Dsympost ∼ Dsymbase + ΔGCaMPz + (1|animal). Model B (shared dose): adds Ic + Ic c2. Model C (condition-specific dose): adds OnTarget + OnTarget×Ic + OnTarget×Ic c2. “B vs. A (on-target)” tests dose structure in on-target trials only; “B vs. A (all)” pools on-target and off-target; “C vs. B” tests whether dose–EPR slopes differ between conditions. βΔGCaMP and its p-value are from Model C.